Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CET

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 AMGEN : Repatha® (Evolocumab) Receives European Commission Approval For New 420 ..
02/15 AMGEN : Amgn) Shares Sold by Amp Capital Investors Ltd
02/14 AMGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
02/14 AMGEN : Submits Supplemental Biologics License Application For BLINCYTO® (Blinat..
02/13 AMGEN, INC. : ex-dividend day
02/09 REGENERON PHARMACEUTICALS INC (NASDA : REGN) And Sanofi SA (ADR)(NYSE:SNY) Loses..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 FDA APPROVES AMGEN, INC. (NASDAQ : AMGN) Drug For Treating Secondary Hyperparath..
02/08 AMGEN : FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatmen..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11:54a 'Safe' NASDAQ Index Dividend Dog Gains Led By Western Digital, Mattel, & Gile..
02/24 Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
02/24 4 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Febr..
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/21 420 mg single-dose monthly delivery option for Amgen's Repatha OK'd in Europe
Advertisement
Financials ($)
Sales 2017 23 092 M
EBIT 2017 11 757 M
Net income 2017 8 094 M
Finance 2017 188 M
Yield 2017 2,62%
P/E ratio 2017 15,98
P/E ratio 2018 15,14
EV / Sales 2017 5,56x
EV / Sales 2018 4,94x
Capitalization 128 555 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 185 $
Spread / Average Target 6,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.19.01%128 555
GILEAD SCIENCES, INC.-3.13%92 143
CELGENE CORPORATION3.21%91 979
REGENERON PHARMACEUTIC..-1.67%38 296
ACTELION LTD22.45%28 792
VERTEX PHARMACEUTICALS..16.37%21 348
More Results